The electronic nose as a diagnostic tool in the discrimination of COPD and controls
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Academic Medical Center Amsterdam, The Netherlands
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
N. Fens, MD1, M.P.C. van der Schee, BSc1, D. Cheung, MD,PhD2, E. Dijkers1, S.B. de Nijs1, P.J.E. Bindels, MD,PhD1, E.H.D. Bel, MD,PhD1 and P.J. Sterk, MD,PhD1. 1Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands and 2Vlietland Hospital, Schiedam, Netherlands. COPD can be Discriminated from Controls by Fingerprint Analysis of Volatile Organic Compounds in Exhaled Air using eNose Technology. Abstract ATS 2008.
- N. Fens, N.Fens@amc.nl, MD1, M.P.C. van der Schee, M.P.C.van_der_Schee@lumc.nl1, S.B. de Nijs, S.B.deNijs@amc.nl1, E. Dijkers, E.Dijkers@amc.nl1, Prof. Dr E.H. Bel, E.H.Bel@amc.nl, MD1 and Prof. Dr P.J. Sterk, P.J.Sterk@amc.nl, MD1. 1Respiratory Medicine, Academic Medical Center, Amsterdam, Netherlands. Exhaled breath molecular profiling in measuring inflammatory status in COPD http://www.ncbi.nlm.nih.gov/pubmed/19713445?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. COPD patients
- •2\. A minimum of ten patients 40\-75 years with moderate to severe COPD:
Exclusion Criteria
- •Two or more of the following:
- •Severe cardiovascular disease, history or present
Outcomes
Primary Outcomes
Not specified